The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large internat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2018
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058241/
https://ncbi.nlm.nih.gov/pubmed/30037803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019414
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg